🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 31 of 55

  1. Lutathera 370 MBq/mL solution for infusion, LysaKare 25 g/25 g solution for infusion

    The George Institute

    Neuroendocrine tumor

    phase 2 small molecule active

    1 trial

  2. Lutetium (177Lu) rhPSMA-10.1 injection

    Blue Earth Diagnostics Ireland Ltd

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  3. Luveltamab tazevibulin

    SUTRO BIOPHARMA, INC.

    Lung Cancer

    phase 2 small molecule terminated

    1 trial

  4. Luveltamab tazevibulin

    SUTRO BIOPHARMA, INC.

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

  5. Luxdegalutamide, DZR123, -, -, DOCETAXEL, CABAZITAXEL, ABIRATERONE, DZR123, ENZALUTAMIDE

    Novartis Pharmaceuticals

    Metastatic castrate resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  6. Luxdegalutamide, GOZETOTIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Pharmaceuticals

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  7. Lynparza 100 mg film-coated tablets, CYCLOPHOSPHAMIDE, Lynparza 150 mg film-coated tablets, DOCETAXEL, DOXORUBICIN, CARBOPLATIN, EPIRUBICIN

    Shanghai Reinovax Biologics Co.,LTD

    Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)

    phase 2 small molecule active

    1 trial

  8. Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Faslodex 250 mg solution for injection., Lynparza 150 mg film-coated tablets, Zoladex 3.6 mg Implant

    Ningbo Cancer Hospital

    ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status.

    phase 2 small molecule active

    1 trial

  9. Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    Fondazione Telethon ETS

    BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer

    phase 2 small molecule active

    1 trial

  10. Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    Wuhan Createrna Science and Technology Co., Ltd

    Basket tumors

    phase 2 small molecule active

    1 trial

  11. Lynparza 150 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Stage IV Non Small Cell Lung Cancer whose tumors lack EGFR mutations and ALK fusions

    phase 2 small molecule active

    1 trial

  12. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    Fondazione Telethon ETS

    recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes

    phase 2 small molecule active

    1 trial

  13. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets, ART6043, ART6043, ART6043, ART6043, ART6043

    Lacuna Pharma Pty Ltd

    Metastatic solid tumors, Advanced solid tumors

    phase 2 small molecule active

    1 trial

  14. LysaKare 25 g/25 g solution for infusion, Lutathera 370 MBq/mL solution for infusion

    Advanced Accelerator Applications

    somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas

    phase 2 small molecule active

    1 trial

  15. Lytgobi 4 mg film-coated tablets, 5-FU medac 50 mg/ml, Injektionslösung, Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Tevimbra 100 mg concentrate for solution for infusion, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion

    The George Institute

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  16. M1774, M1774, M1774, M1774, M4076, Zejula 100 mg film-coated tablets

    Merck Sharp and Dohme

    Epithelial ovarian cancer that progressed on prior PARP inhibitor therapy

    phase 2 small molecule active

    1 trial

  17. M9140

    Merck Sharp and Dohme

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  18. M9140

    Merck Sharp and Dohme

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. M9140

    Serono Europe Limited

    Solid Tumors

    phase 2 small molecule active

    1 trial

  20. M9140

    Merck Sharp and Dohme

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  21. MB-huCART19.1

    AXIM BIOTECHNOLOGIES, INC.

    B-cell precursor ALL, B-cell Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  22. MB07133 300mg/m2/day

    LIGAND PHARMACEUTICALS INC

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  23. MBG453, VENETOCLAX, VENETOCLAX, AZACITIDINE, VENETOCLAX

    Novartis Pharmaceuticals

    intermediate, high or very high risk MDS in adult patients chronic Myelomonocytic Leukemia - 2 (CMML-2) Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy

    phase 2 small molecule active

    1 trial

  24. MCLA-128

    Partner Therapeutics Limited

    Solid Tumors

    phase 2 small molecule active

    1 trial

  25. MDNA11

    Medicenna Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  26. MEDI4736

    AstraZeneca

    Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

    phase 2 small molecule completed

    1 trial

  27. MERCAPTOPURINE, PREDNISONE, VINCRISTINE SULFATE, CYTARABINE, FILGRASTIM, LENOGRASTIM, CYTARABINE, IDARUBICIN HYDROCHLORIDE, FOLINIC ACID, Iclusig 15 mg film-coated tablets, METHYLPREDNISOLONE SODIUM SUCCINATE, CYCLOPHOSPHAMIDE, METHOTREXATE, METHOTREXATE, DEXAMETHASONE DISODIUM PHOSPHATE, Iclusig 15 mg film-coated tablets

    Fondazione Telethon ETS

    Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.

    phase 2 small molecule active

    1 trial

  28. METFORAL 850 mg compresse rivestite con film

    Fondazione Telethon ETS

    Triple negative breast cancer

    phase 2 small molecule active

    1 trial

  29. METFORMIN

    Istituto Gentili S.r.l.

    bone sarcoma

    phase 2 small molecule active

    1 trial

  30. MIDAZOLAM , ODM-208 100 mg Tablet, ODM-208 50 mg Tablet, ODM-208 25 mg Tablet, ODM-208 5 mg film-coated tablet

    Orion Laboratories Pty.

    Metastatic castration-resistant prostate cancer.

    phase 2 small molecule active

    1 trial

  31. MIE

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 other active

    1 trial

  32. MK-1022, -, -, -

    Merck Sharp and Dohme

    Colorectal Carcinoma, Biliary Tract Carcinoma, Hepatocellular Carcinoma​

    phase 2 small molecule active

    1 trial

  33. MK-1022, -, MK-1084, MK-1084, MK-2870, MK-1084, CETUXIMAB , MK-1084

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  34. MK-1045

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  35. MK-3120

    Merck Sharp and Dohme

    High-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors

    phase 2 small molecule active

    1 trial

  36. MK-3120

    Merck Sharp and Dohme

    Advanced/metastatic solid tumor disease

    phase 2 small molecule active

    1 trial

  37. MK-3475A

    Merck Sharp and Dohme

    Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)

    phase 2 small molecule active

    1 trial

  38. MK-4830, Lenvatinib, Lenvatinib, Belzutifan, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4280A, MK-1308A

    Merck Sharp and Dohme

    Renal cell carcinoma

    phase 2 small molecule active

    1 trial

  39. MKC-1

    CASI Pharmaceuticals

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  40. MKC-1

    CASI Pharmaceuticals

    Advanced Cancer

    phase 2 small molecule completed

    2 trials

  41. MKC-1

    CASI Pharmaceuticals

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  42. MKC-1

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  43. MLN0264

    Takeda

    Pancreatic Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  44. MLN0264

    Takeda

    Adenocarcinoma of the Stomach

    phase 2 small molecule terminated

    1 trial

  45. MOGAMULIZUMAB

    Ningbo Cancer Hospital

    Cutaneous T-cell lymphoma, a category of cancers of lymphocytes (a type of white blood cells) that primarily involve the skin, Cutaneous T-cell lymphoma (Mycosis Fungoides (MF)) and Sézary Syndrome (SS))

    phase 2 small molecule active

    1 trial

  46. MRG003

    Shanghai University of Traditional Chinese Medicine

    Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

    phase 2 small molecule active

    1 trial

  47. MRG003 combined with Dalpicicilip

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  48. MRG003 combined with Pucotenlimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.